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Recent clinical and pre-clinical research suggests that affective biases may play an important 
role in the development and perpetuation of mood disorders. Studies in animals have also 
revealed that similar neuropsychological processes can be measured in non-human species 
using behavioural assays designed to measure biases in learning and memory or decision-
making. Given the proposed links between hormones and mood, we used the affective bias test 
to investigate the effects of different hormone treatments in both male and female rats.  Animals 
were pre-treated with acute doses of hormone or vehicle control prior to learning each of two 
independent substrate-reward associations. During a subsequent choice test, positive or 
negative biases were observed by animal’s preference towards or away from the substrate learnt 
during drug treatment respectively. In both sexes, oestradiol and the oestrogen-like compound 
bisphenol A induced positive biases, whilst blockade of oestrogen hormones with formestane 
induced a negative bias. Progesterone induced a negative bias in both sexes, but testosterone 
only induced a negative bias in males. Blocking testosterone with flutamide induced a positive 
bias in both sexes at the higher dose (10mg/kg). The oxytocin analogue, carbetocin induced 
positive biases in both sexes but the vasopressin analogue, desmopressin, induced a positive 
bias in male rats only. These results provide evidence that modulating levels of hormones using 
exogenous treatments can induce affective biases in rats. They also suggest that hormone-
induced affective biases influence cognitive and emotional behaviour and could have longer-





• The affective bias test provides new insights into the relationship between mood-related 
hormones and affective biases in rats. 
 
• Treatment with oestradiol, bisphenol A and carbetocin induced significant positive 
affective biases in both male and female rats, whilst desmopressin induced a positive 
affective bias in males only. 
 
• The opposite effects to oestradiol were found following formestane treatment, inducing 
a negative affective bias in both sexes. 
 
• In male rats, a negative affective bias was developed following treatment with the low 
dose of progesterone, whilst in females following the higher dose of progesterone. 
 
• Testosterone induced a dose-dependent negative affective bias in males, whilst in 
females there was no effect found. A positive affective bias was developed in both 



















Recent findings suggest that affective biases (the process whereby cognitive functions such as 
learning and memory and decision-making are modified by emotional state), may play an 
important role in the cause and treatment of depression (Harmer et al., 2017; Robinson, 2018). 
It is hypothesised that negative affective biases contribute to the reinforcement of negative 
feelings and beliefs in depression (Disner et al., 2011). Antidepressants have been shown to 
induce positive affective biases which is thought to influence the reversal of symptoms of 
depression over time (Harmer et al., 2017). Studies in both human and non-human species have 
shown that affective biases can influence many different cognitive domains (Roiser et al., 2012; 
Robinson, 2018). These include findings that people with anxiety and/or depression tend to 
exhibit biases in attention, memory and decision-making particularly in relation to ambiguous 
information or future events (Mogg et al., 2006; Roiser et al., 2012). Most studies in humans 
investigate the processing of emotional information and show that depression is associated with 
reduced positive and/or enhanced negative biases in emotional interpretation and emotional 
memory (Roiser et al., 2012). For example, depressed patients show greater recall of negative 
stimuli and exhibit faster reaction times to sad faces versus happy faces (Disner et al., 2011; 
Elliott et al., 2011; Roiser et al., 2012). Antidepressant treatments have also been shown to 
positively bias emotional processing in both healthy volunteers and patients which importantly, 
can occur after acute or short-term treatment and before subjective changes in mood become 
apparent (Mogg et al., 2006; Roiser et al., 2012). Building on these empirical observations and 
underlying neuropsychological hypotheses, tasks have been developed for non-human species 
which may facilitate quantification of similar affective biases (Mendl et al., 2009; Hales et al., 
2014; Robinson, 2018). 
 
Since the first report of an affective bias task for rats (Harding et al., 2004), two types of 
behavioural assay for non-human species have been developed. The judgement bias task (also 
called the ambiguous cue interpretation task) is designed to quantify affective biases in a two-
choice decision-making task (for review see, Hales et al., 2014). Animals are first trained to 
associate two distinct cues with positively or negatively-valenced outcomes. Biases in 
decision-making are then quantified by presenting the animals with intermediate, ambiguous 
cues and recording their responses. More positive affective states are associated with a greater 
number of responses in anticipation of positive outcomes during ambiguous cue presentation. 
Studies using pharmacological and phenotypic models suggest that these biases are generally 
consistent with predicted changes in the underlying affective state, although there are 
exceptions (for review and more detailed discussion see, Hales et al., 2014). The affective bias 
test (ABT), first reported in 2013, is designed to quantify biases linked to learning and memory 
(for review see, Hales et al., 2014; Robinson, 2018). The assay uses a within-subject study 
design where animals encounter two distinct and independent learning experiences under 
treatment or control conditions. The value of the experiences is kept constant and, using a 
choice test, biases resulting from the treatment can be quantified. Treatments inducing a 
positive bias result in a preference for the treatment-paired experience, whilst negative biases 
are observed as a preference for the control paired experience. The ABT has been extensively 
validated using pharmacological, psychosocial and neurobiological studies with results 
consistent with predicted effects on affective state (Stuart et al., 2013, 2015; Hinchcliffe et al., 
2017; Stuart et al., 2017). 
 
In this study, we used the ABT to investigate the effects of the gonadal hormones, oestrogen, 
progesterone and testosterone, and peptide hormones, oxytocin and vasopressin on biases in 
learning and memory in both male and female rats. The gonadal hormones and the peptide 
hormones have been linked to changes in emotional processing and mood (Swaab et al., 2005; 
Neumann and Landgraf, 2012; Backstrom et al., 2014; McHenry et al., 2014). These hormones 
play important roles in modulating normal sexual and social behaviour but, may also contribute 
to the development of mood-related symptoms in mental health disorders, and the emotional 
symptoms associated with premenstrual, postpartum and menopausal disorders (Backstrom et 
al., 2014; Swaab et al., 2005). Previous studies suggest that elevated oestradiol is associated 
with more positive affective states including reduced anxiety and antidepressant effects (Albert 
and Newhouse, 2019). In contrast, progesterone has been linked to low mood, and induction 
of premenstrual syndrome or premenstrual dysphoric disorder (Swaab et al., 2005; Backstrom 
et al., 2014). The effects of testosterone in a rodent model of depression suggested an 
antidepressant effect (Buddenberg et al., 2009). On the other hand, high levels of testosterone 
increase aggression behaviours in men and in male rats (Finkelstein et al., 1997; Rosell and 
Siever, 2015). Testosterone can also modulate the stress response, although with different 
outcomes reported. For example, some studies report increased responsiveness (Mehta et al., 
2008), whilst others suggest a reduction in the stress response (Stephens et al., 2016). Although 
previous studies have shown links between hormone levels and emotional behaviour, their 
effects on affective biases is unknown. There have also been issues in the interpretation of 
previous studies in rodent models of depression given the limitations associated with these 
approaches (Slattery and Cryan, 2017). In particular, conventional methods of assessing 
emotional behaviour in rodents have limited translational validity and generally rely on stress 
related methods. Furthermore, there is a lack of consistency in terms of the depression-like 
phenotype which develops in males versus females which do not necessarily reflect sex 
differences in clinical populations (Kokras and Dalla, 2014). Thus, to further understand the 
effects of the gonadal hormones on affective biases, we tested the both androgen hormones and 
androgen receptor antagonists, flutamide, and aromatase inhibitor, formestane. There is also a 
detailed literature investigating the role of oxytocin and vasopressin and how they contribute 
to emotional behaviour (Neumann and Landgraf, 2012). It has previously been reported that 
oxytocin has antidepressants effects in the forced swim test (FST) (Balmus et al., 2018). In 
contrast, vasopressin neurons in the paraventricular nucleus are activated in depressed patients 
and have functional consequences for hypothalamic-pituitary-adrenal (HPA) axis responsivity 
(Neumann and Landgraf, 2012). Studies in rodents suggest that vasopressin V1b antagonists 
have both anxiolytic and antidepressant-like effects (Iijima et al., 2014). Due to the short half-
lives and poor bioavailability of the peptide hormones, we tested the stable analogues 
carbetocin and desmopressin (Broadbear et al., 2014). We also tested the proposed endocrine 
disruptor bisphenol A which may mimic oestradiol and is a common component of everyday 
items e.g. plastic bottles, water pipes, CDs etc. (see report, EFSA panel, 2015). These results 
provide new insights into how these hormones modulate affective biases and illustrate possible 
implications for effects on mood considering the neuropsychological hypothesis of depression 
(Robinson, 2018). 
2. METHODS 
2.1. Animals and housing 
Subjects were twelve male and twelve female Sprague Dawley rats (Charles River, UK) run as 
independent cohorts. Males weighed approximately 300−350 g and females weighed 200−250 
g at the start of experimental manipulations. Animal weights were checked daily and their 
growth monitored weekly against a standard curve for Sprague Dawley rats. All animals were 
housed in same-sex pairs in enriched laboratory cages (55 × 35 × 21 cm) with sawdust, paper 
bedding, cotton rope, cardboard tubes and red Perspex houses (30 × 17 × 10 cm), in 
temperature-controlled conditions (21 ± 1 °C) and under a 12:12 h reverse light–dark cycle 
(lights off at 07:00 h). Rats were mildly food restricted to approximately 90 % of their free 
feeding weights (∼18 g of food per rat/day laboratory chow (Purina, UK)). Female rats were 
housed in a room with male animals to help maintain a normal oestrus cycle. Water was freely 
available, except during the pairing and test sessions in the affective bias test and the 
consumption test. The behavioural procedures and testing were performed during the animals’ 
active phase between 09:00 h and 17:00 h. All experimental procedures were conducted in 
accordance with the UK Animals (Scientific Procedures) Act 1986 and were approved by the 
local ethical review group (University of Bristol). 
 
2.2. Affective bias test (ABT) 
2.2.1. General protocol 
All testing was carried out in a perspex arena (40 × 40 cm) with two ceramic bowls (Ø 10 cm) 
and a range of digging substrates (reward-paired substrates - ‘CS + A’ or ‘CS + B’ versus 
unrewarded substrate – ‘CS-’, matched for digging effort, see supplementary materials, Table 
S1). The experimental training and testing for ABT were similar to those previously described 
(Stuart et al., 2013, 2015; Hinchcliffe et al., 2017). The training protocol consisted of 
habituation to the arena and three digging training sessions (20 trials per session) with a bowl 
filled with increasing amounts of digging substrate (sawdust) to obtain food reward (one 45 
mg purified rodent tablet, Test Diet, Sandown Scientific, UK, catalogue number #1811155, 
containing sucrose, casein, maltodextrin, corn starch, corn oil, minerals, vitamins, magnesium 
stearate, DL-methionine). Once each animal was able to find the food pellet within 30 s on 10 
consecutive trials, the digging training was complete. On the last day of training, animals 
underwent a discrimination session allowing them to explore two bowls with two novel digging 
substrates (reward-paired substrate, CS+, with single pellet versus unrewarded substrate CS-). 
A reward pellet was crushed into the bowl and mixed within the unrewarded substrate, to avoid 
choices based on odour. On each trial, the animal was individually placed in front of the two 
bowls. Once the animal made a choice and started digging in one bowl, the other bowl was 
removed by the experimenter. Choice of the reward-paired substrate was marked as a ‘correct’ 
trial, digging in the CS- substrate was classified as an ‘incorrect’ trial and if an animal failed 
to approach and explore the bowls within 30 s, the trial was recorded as an ‘omission’. Trials 
were continued until the rat achieved six consecutive correct choices for the reward-paired 
substrate. All animals completed training and were included in the subsequent studies (n = 12 
per cohort). 
 
2.2.2. Hormone dose-response studies 
All studies were based on four pairing sessions (one per day) followed by a choice test on the 
fifth day of that week. Each pairing session followed the same procedures as the discrimination 
session detailed above. During four pairing sessions, each animal learnt to associate two 
different digging substrates with acquiring a food reward under vehicle or treatment conditions. 
Each trial involved a choice between two bowls containing two different digging substrates, 
one reward-paired (‘CS + A’ or ‘CS + B’, containing a single reward pellet, counterbalanced 
by treatment) and the other an unrewarded CS- substrate. The CS- digging substrate was kept 
the same for the four pairing sessions and a reward pellet was crushed into the bowl and mixed 
within the substrate. CS + A was either presented on days 1 and 3 of the pairing sessions or on 
days 2 and 4, and CS + B was presented on the other two days. This was counterbalanced for 
animals and treatment. Presentation of one of these substrates (the ‘treatment-paired substrate’) 
was associated with administration of the drug treatment whilst the other was associated with 
vehicle treatment. The value of each experience was equal (one reward pellet) and all factors 
(i.e. bowl location, substrates, pairing sessions, hormone treatments) were fully 
counterbalanced. The number of trials to reach the discrimination criterion on each day, and 
response latency to dig were recorded for each animal. 
 
Affective biases were quantified during the choice test on day 5 in which the two previously 
rewarded substrates (‘CS + A’ and CS+‘B’) were presented at the same time for 30 trials. Trials 
were reinforced using a random schedule with a single-pellet reward baited in either bowl with 
a probability of one in three. Both bowls contained a crushed pellet to reduce the likelihood of 
the animal using odour to find the reward. The animals’ choices and latency to dig were 
recorded. 
 
2.3. Consumption test 
To assess whether gonadal hormone treatments have any effects on appetite and food intake, 
we used a consumption test where the quantity of food (reward pellets, 45 mg pellets, Test 
Diet, UK) consumed by an animal within 10 min was measured. To match experimental 
conditions with the ABT, animals subjected to this consumption test were mildly food 
restricted and hormones were injected 30 min prior to testing. The consumption test was carried 
out in the ABT arena with one pottery bowl (Ø 5 cm). The study took place over four non-
consecutive days using a fully counterbalanced design with the dose of each hormone that 
induced the largest affective bias being administered on each day followed by a food 
consumption test. Doses used were: oestradiol (males 1.0 μg/kg, females 10.0 μg/kg), 
progesterone (males 1.0 mg/kg, females 10.0 mg/kg), testosterone (males 10.0 mg/kg, females 
10.0 mg/kg) and vehicle. Each animal was placed in the arena with the bowl containing 50 g 
of food reward pellets. Once the Perspex lid of the arena was closed, the test began. After 10 
min, the rat was put back into the home cage and the uneaten food recovered, weighed and 
recorded. The bowl was re-baited for each animal. Absolute consumption was calculated as 
weight (in grams) of food left in the bowl subtracted from total weight of food placed in the 
bowl. The rats were weighed before every day of testing to allow calculation of consumption 
relative to body weight (grams/kilograms). 
 
2.4. Drugs 
Oestradiol (17β-estradiol; 1.0, 10.0 μg/kg, administered subcutaneously: SC, t=-30 min), 
progesterone (4-Pregnene-3,20-dione; 1.0, 10.0 mg/kg, SC, t=-30 min), testosterone (1.0, 10.0 
mg/kg, SC, t=-30 min), formestane (1.0, 10.0 mg/kg, SC, t=-30 min), flutamide (1.0, 10.0 
mg/kg, administered orally: PO, t=-30 min), bisphenol A (0.05, 0.5 mg/kg, PO, t =-30 min), 
carbetocin (carbetocin acetate; CBT; 0.3 mg/kg, SC, t=-15 min), and desmopressin ([deamino-
Cys1, d-Arg8]-Vasopressin acetate salt hydrate; DDAVP; 0.1 mg/kg, SC, t=-15 min) were 
purchased from Sigma-Aldrich, UK. Choice of doses was based on previous studies (Swaab et 
al., 2005; Neumann and Landgraf, 2012; Backstrom et al., 2014; McHenry et al., 2014). Single 
low doses of desmopressin has been found to activate the HPA axis and lead to cortisol release 
in human participants suggesting it crosses the blood brain barrier (Scott et al., 1999). Vehicle 
solution for oestradiol, progesterone, testosterone and formestane was 5% DMSO and 95 % 
sesame oil; for flutamide and bisphenol A was 1% ethanol in strawberry milkshake, and for 
carbetocin and desmopressin was saline. Prior to the start of the experiments, rats were trained 
to drink milkshake (Frijj, UK, 0.5 ml) from a 1 ml syringe to facilitate oral drug dosing. On 
each day of treatment, drugs and vehicle solutions were freshly prepared. All studies used a 
within-subject design and there was a minimum of 7 days drug free before commencing a new 
treatment. All subcutaneous injections were performed with minor animal restraint and injected 
on their left or right flank (changing daily) to minimise the stress associated with restraint. All 
experiments were carried out with the experimenter blind to treatment. 
3. DATA ANALYSIS 
Data were analysed and the graphs were created using GraphPad Prism 6.0 (GraphPad 
Software, USA). Choice bias was calculated as the number of choices made for the treatment-
paired substrate divided by the total number of trials (treatment-paired substrate + vehicle-
paired substrate) multiplied by 100 to give a percentage value. A value of 50 was then 
subtracted to give a % choice bias score where a bias towards the treatment-paired substrate 
gave a positive value and a bias towards the vehicle-paired substrate gave a negative value. 
 
The % choice bias results from the dose response studies were analysed using a repeated 
measures ANOVA with dose (oestradiol, formestane, bisphenol A, progesterone, testosterone 
and flutamide study) or treatment (carbetocin and desmopressin study) as the within-subject 
factor, and one-sample t-test against the null hypothesised mean of 0% choice bias as post-hoc 
tests. A Shapiro-Wilk test was used to determine a normal distribution, the Huynh-Feldt 
correction was used to adjust for violations of the sphericity assumption, and Levene’s test was 
used to correct for inequality of variances for the % Choice bias. A repeated measures ANOVA 
with treatment as the within-subject factor was used to analyse the results from consumption 
test. Analysis of the trials to criterion and response latency utilised a paired t-test, comparing 
vehicle vs treatment for each animal during the pairing sessions. 
 
4. RESULTS 
4.1. Effects of acute hormone manipulations on affective biases in male and female rats 
Animals made significantly more choices for the substrate-reward association learnt following 
acute treatment with female gonadal hormone, oestradiol (males, 0.0–10.0 μg/kg, RM ANOVA 
F2,11 = 4.033, p = 0.0322, Fig. 1A and females, 0.0–10.0 μg/kg, RM ANOVA F2,11 = 7.005, 
p = 0.0044, Fig. 2A), endocrine disruptor, bisphenol A (males, 0.0-0.5 mg/kg, RM ANOVA 
F2,9 = 6.339, p = 0.0082, Fig. 1A and females, 0.0-0.5 mg/kg, RM ANOVA F2,10 = 4.085, p 
= 0.0325, Fig. 2A), and androgen receptor antagonist, flutamide (males, 0.0–10.0 mg/kg, RM 
ANOVA F2,10 = 4.593, p = 0.0228, Fig. 1B and females, 0.0–10.0 mg/kg, RM ANOVA F2,10 
= 7.100, p = 0.0047, Fig. 2B) indicating positive affective biases. Positive biases were observed 
for both 1.0 and 10.0 μg/kg doses of oestradiol in males (one sample t-test, t11= 8.208, p < 
0.0001 and t11= 3.169, p = 0.0089 respectively) and 10 μg/kg in females (one sample t-test, 
t11= 5.204, p = 0.0003) with a trend towards an effect at 1 μg/kg (one sample t-test, t11= 1.857, 
p = 0.09), for both 0.05 mg/kg and 0.5 mg/kg doses of bisphenol A in males (one sample t-test, 
t9= 6.000, p = 0.0002 and t9 = 4.385, p = 0.0018 respectively) and in females (one sample t-
test, t10 = 5.333, p = 0.0003 and t10= 5.190, p = 0.0004 respectively), but only for the higher 
dose of 10 mg/kg of flutamide in males (one sample t-test, t10 = 5.043, p = 0.0005) and in 
females (one sample t-test, t10 = 3.985, p = 0.0026). 
Progesterone treatment in males (0.0–10.0 mg/kg, RM ANOVA F2,11 = 4.592, p = 0.0215, 
Fig. 1B) induced a negative bias effect only at a low dose of 1.0 mg/kg (one sample t-test, t11 
= 3.084, p = 0.0104), whilst in females (0.0–10.0 mg/kg, RM ANOVA F2,11 = 19.70, p = 
0.0001, Fig. 2B) only at a high dose of 10.0 mg/kg (one sample t-test, t11 = 7.416, p < 0.0001). 
 
Acute treatment with the male gonadal hormone, testosterone induced a negative bias in males 
only (0.0–10.0 mg/kg, RM ANOVA F2,10 = 19.80, p = 0.0001, Fig. 1B) for both 1.0 mg/kg 
and 10.0 mg/kg doses of testosterone (one sample t-test, t10 = 5.926, p = 0.0001 and t10 = 
8.150, p < 0.0001 respectively). Testosterone treatment in females did not show any effects 
(0.0–10.0 mg/kg, RM ANOVA F2,10 = 0.9265, p = 0.4123, Fig. 2B). The aromatase inhibitor, 
formestane induced positive biases in both sexes (males, 0.0–10.0 mg/kg, RM ANOVA F2,11 
= 6.897, p = 0.0047, Fig. 1A and females, 0.0–10.0 mg/kg, RM ANOVA F2,10 = 18.58, p = 
0.0001, Fig. 2A), and with effects observed for both 1.0 and 10.0 mg/kg doses of formestane 
in males (one sample t-test, t11= 2.244, p = 0.0463 and t11 = 3.736, p = 0.0031 respectively) 
and females (one sample t-test, t9= 5.014, p = 0.0007 and t9= 6.194, p = 0.0002 respectively), 
 
Oxytocin and vasopressin analogues induced positive biases in male rats (RM ANOVA, F2,33 
= 5.491, p = 0.0090, Fig. 3, carbetocin 0.3 mg/kg, one sample t-test, t11 = 5.745, p = 0.0001, 
Fig. 3) and desmopressin (0.1 mg/kg, one sample t-test, t11 = 6.189, p < 0.0001, Fig. 3). Female 
rats (RM ANOVA, F2,33 = 1.099, p = 0.3452, Fig. 3) treated with the oxytocin analogue 
developed a positive bias (one sample t-test, t11 = 3.559, p = 0.0045), while vasopressin 
analogue showed no effect. 
There were no significant effects of treatment during pairing sessions, either on response 
latency or number of trials to criterion following all hormone manipulations (see 
Supplementary materials, Table S2 and S3). 
 
4.2. Consumption test 
In the voluntary pellet consumption test male animals under different treatments did show 
significant main effect in the absolute consumption (RM ANOVA F3,33 = 4.450, p = 0.010, 
Fig. 4A) but did not in the absolute consumption per body weight [g/kg] (RM ANOVA F3,33 
= 2.823, p = 0.054, Fig. 4C). Study using female animals shown main effects in the absolute 
consumption (RM ANOVA F3,30 = 7.785, p = 0.0005, Fig. 4B) and in the absolute 
consumption per body weight [g/kg] (RM ANOVA F3,30 = 8.132, p = 0.0004, Fig. 4D). Post 
hoc Dunnett’s test revealed no significant differences in both males and females in the absolute 
consumption between the vehicle and hormone treatments, and also in the absolute 
consumption per body weight in males. The only changes were found in females between the 
vehicle and progesterone in the absolute consumption per body weight. Females consumed less 
reward pellets after progesterone treatment than vehicle (p = 0.045, Fig. 4D). 
 
5. DISCUSSION 
Our studies have shown that acute hormone treatments can induce affective biases in male and 
female rats. The effects, in terms of induction of a positive or negative bias, were similar for 
both sexes but with some exceptions. In both sexes, treatment with oestradiol and bisphenol A 
and the oxytocin analogue, carbetocin, induced a positive bias. The vasopressin analogue, 
desmopressin, induced a positive bias but only in male rats. The lower dose of progesterone 
induced a negative bias in male rats, but only the higher dose was significantly effective in 
female rats. Testosterone treatment induced a negative bias in male rats but had no effect in 
females. When the effects of the gonadal hormones were blocked, the opposite effects were 
seen. Both the low and high dose of formestane induced a negative bias in male and female 
rats. Interestingly, despite the lack of effect of testosterone in the female animals, flutamide 
induced positive biases in both sexes. Data from pairing sessions indicated no effects of 
treatment on the number of trials to reach criterion or latency to dig in the bowls under all 
experimental manipulations. None of the compounds induced non-specific effects (e.g. 
motivation changes, sedation) in animals compared to vehicle treatments. Consumption tests 
in both male and female rats did not reveal any clear changes in appetite when compared with 
vehicle treatment although there were main effect findings with the ANOVA. The only change 
was found in females’ consumption per body weight, who consumed less reward pellets after 
progesterone treatment than vehicle. 
 
Oestradiol treatment induced a positive bias in male and female rats, whilst blocking its effects 
using formestane induced a negative bias. These effects are consistent with those observed in 
conventional models of depression where oestradiol treatment has an antidepressant effect in 
the FST in intact animals (Walf and Frye, 2005) and gonadectomized animals (Carrier et al., 
2015). Previous studies in humans have found that high levels of oestradiol can alter emotional 
learning by protecting hippocampal activity and its plasticity and reducing the psychological 
effects of stress (see review, Albert and Newhouse, 2019). Oestradiol has also been shown to 
have effects on emotional memory, by attenuating recall of negative emotional stimuli 
(Wegerer et al., 2014). In rats, intra-amygdala infusions of oestradiol reduced depressive 
behaviours in the FST (Frye and Walf, 2004). Previous studies found that the amygdala plays 
a crucial role in development of the affective biases (Stuart et al., 2015) suggesting this may 
be an important locus for the effects observed with oestradiol in these experiments. It has also 
been suggested that elevated levels of oestrogen modulate HPA axis activity and reduce the 
physiological and psychological stress response (Albert and Newhouse, 2019). Interestingly, 
we also observed positive biases in rats treated with bisphenol A. BPA binds to both alpha and 
beta oestrogen receptors, and therefore can mimic oestrogens effects (EFSA report, 2015). In 
the ABT the effects of BPA are similar to those seen with oestradiol suggesting that acute 
exposure to these levels of the compound can have oestrogen-like effects on emotional 
behaviour. It should be noted that doses of 50 μg/kg and 500 μg/kg were used in this study 
based on the guidelines in the European Food Safety Authority (EFSA) report, which 
recommended a Tolerable Daily Intake (TDI) of 50 μg/kg (EFSA report, 2015). However, in 
2017 EFSA changed this to 4 μg/kg. 
 
To further investigate the effects of endogenous oestradiol we used, formestane, a selective 
aromatase inhibitor. Acute administration of formestane induced a dose-dependent negative 
bias, the opposite effect to oestradiol treatment suggesting inhibition of endogenous oestradiol 
has negative effects on emotional behaviour in both sexes. It previously has been shown that 
formestane inhibits oestrogen synthesis in the brain, and by inhibiting the conversion of 
androgens into oestrogens (Dowsett, 1994). Acute formestane treatment lacks effects in FST 
(Martinez-Mota et al., 2008), but does attenuate antidepressant-like actions of fluoxetine and 
desipramine suggesting oestradiol may contribute to these drugs antidepressant effects 
(Martinez-Mota et al., 2008). Previous studies in the ABT have shown that acute treatments 
which induce a negative bias also have higher levels of pro-depressant effects in man and can 
cause impairments in reward processing following chronic treatment (Stuart et al., 2017). 
Formestane was used in the treatment of breast cancer and these data suggest that long term 
use may have caused mood related side effects (Wiseman and Goa, 1996). 
 
Acute treatment with progesterone induced a negative bias in the ABT consistent with its 
predicted effects on mood and association with negative emotional states including irritability, 
aggression and the development of premenstrual syndrome or postnatal depression (Swaab et 
al., 2005; Backstrom et al., 2014). In the forced swim test, progesterone administered at similar 
doses caused an increase in immobility time, suggesting a pro-depressant-like effect in mice 
(Kaur and Kulkarni, 2002). Progesterone can also have effects through its active metabolite, 
allopregnanolone which can act indirectly as a modulator of the GABAA receptor complex and 
induce negative effects on emotional behavior (Backstrom et al., 2014). Interestingly, there 
have been some discrepancies in the literature in relation to progesterone’s effect on mood (see 
review, Backstrom et al., 2014) however, our studies suggest that increasing the levels of this 
hormone acutely can lead to negative affective biases. In humans, higher progesterone levels 
have been shown to enhance memory for negative emotional images (Ertman et al., 2011) and 
intrusive recollections of negative emotional events (Ferree et al., 2011). 
 
In the ABT, we observed no effect with testosterone treatment in female rats but a negative 
bias following acute dosing in males. These findings are opposite to those previously reported 
for the forced swim test where an antidepressant like effect was observed (Buddenberg et al., 
2009). Castrated male rats were also observed to have more depression-like behaviours in this 
assay suggesting low testosterone levels may be pro-depressant however, there are limitations 
associated with the forced swim test (McHenry et al., 2014). The antidepressant-like effects of 
testosterone have been linked to its conversions into oestradiol, as treatment with 
dihydrotestosterone, a testosterone metabolite that cannot be aromatised to oestradiol, did not 
induce the same effect (McHenry et al., 2014). However, we previously observed positive 
biases with oestradiol in the ABT in male rats and therefore, this does not appear to be a 
mechanism contributing to the effects observed in this assay. We also observed that blocking 
the effects of testosterone induced a positive bias suggesting these effects were hormone 
specific. Again, these effects are not generally the same as has previously been reported 
although aspects of the experimental protocols do differ. For example, neonatal treatment with 
flutamide has been shown to increase depression and anxiety-like behaviours in rats (Zhang et 
al., 2010). In contrast, tests evaluating anxiety-like behaviours using an open field test and a 
modified Vogel’s conflict model, have demonstrated anxiolytic properties following flutamide 
treatment (Svensson, 2012). In humans, cancer treatments involving androgen blockade have 
also been linked to adverse effects on cognition and mood (Cherrier et al., 2009). The ability 
of flutamide treatment to induce positive biases in both sexes may be related to its effects on 
serum levels of oestradiol (O’Connor et al., 2002). Whilst differences in the assays used or 
time course of treatment may be relevant, another possible cause of the negative bias in male 
rats is that treatment may have induced an increase in inter-male aggression which can then 
cause psychosocial stress. One of the most widely used rodent models of depression is the 
chronic social defeat model (Rygula et al., 2005) and studies in the affective bias tasks have 
previously reported negative affective biases in rats exposed to both acute and chronic 
psychosocial stress (Papciak et al., 2013; Stuart et al., 2013; Hinchcliffe et al., 2017). 
 
We observed a positive affective bias of oxytocin in both male and female rats in the ABT. 
These data suggest that as well as having effects on social behaviour and in other measures of 
emotional processing (Neumann and Landgraf, 2012), acute doses of oxytocin can induce 
positive affective biases. These findings are consistent with other rodent studies where acute 
oxytocin (Balmus et al., 2018) as well as carbetocin (Broadbear et al., 2014) treatment reduces 
immobility in the forced swim test in rats. Interestingly, in a judgement bias task in dogs, 
oxytocin was found to induce a positive affective bias (Kis et al., 2015). Higher levels of 
oxytocin are a potential biomarker of positive emotion in dogs and humans, and a facilitator of 
pro-social behaviour in rodents (Kis et al., 2015). A study in humans has also shown that 
oxytocin can reduce cortisol levels in humans during stress conditions (Cardoso et al., 2013). 
We also observed positive biases in male but not female rats, when animals were treated with 
desmopressin. These effects are contrary to previous findings, where anxiogenic effects have 
been reported (Mak et al., 2012) and treatment with vasopressin antagonists have had 
antidepressant effects (Iijima et al., 2014). Desmopressin interacts with AVP1 receptors, which 
would be expected to increase aggressive behaviour and cause psychosocial stress and negative 
biases. However, we used a very low dose of desmopressin because of its powerful antidiuretic 
properties. If it could be done safely (e.g. avoiding water retention, low blood sodium and 
seizures, Verbalis, 1993), use of a higher dose would be desirable to investigate dose 
dependency of any induced biases. It would also be interesting to test the vasopressin receptor 
1 antagonists, which have previously been found to have anxiolytic and antidepressant effects 
and are selective for the AVP1 receptor thus reducing effects associated with fluid homeostasis. 
 
The ABT is an appetitive task, however, we have previously reported effects for a wide range 
of compounds which are in a direction that does not consistently relate to changes in motivation 
or appetite (Stuart et al., 2013, 2015; Hinchcliffe et al., 2017; Stuart et al., 2017). However, 
previous studies have shown that sex hormone manipulations may affect appetite and food 
intake (Krishnan et al., 2016). The results from our voluntary consumption test did not find any 
effects of oestrogen, progesterone or testosterone on appetite when compared to the vehicle 
group although there was some variation in the data and differences between vehicle and 
progesterone in absolute consumption per body weight female rats. This finding seems to be 
the opposite of that observed in previous preclinical studies. Authors have demonstrated that 
acute progesterone treatment (10 mg/kg) causes an increase in appetite in female mice (Kaur 
and Kulkarni, 2002). There was also no effect on latencies during the task consistent with a 
lack of effect on motivation or general locomotor function. 
 
In summary, this study has shown that acute manipulation of gonadal hormone levels using 
exogenous administration or treatment with antagonists can induce biases in reward learning 
and memory in the ABT. Both male and female rats were similarly affected by the peptide 
hormones and female gonadal hormones but with differences in their response to testosterone. 
There is growing interest in the relationship between affective biases and mood disorders and 
these data suggest that hormones may also be an important modulator of these biases (Hales et 
al., 2014; Stuart et al., 2017; Robinson, 2018). Both our studies in rodents and work in humans 
suggest that there is a direct relationship between the ability of an acute treatment to induce an 
affective bias and their longer-term impacts on mood (Harmer et al., 2017; Stuart et al., 2017; 
Robinson, 2018). At this time, we have only looked at the acute effects of these hormones and 
further studies to investigate chronic treatments and affective biases during fluctuations in 
hormone levels (e.g. following withdrawal) would also be of interest. The effects of these 
treatments on the acute and chronic effects of stress (Guo et al., 2018) is also an area of interest 
and could be further investigated using the ABT and our assay of reward-induced bias, which 
is sensitive to impairments in a range of putative depression models (Stuart et al., 2017; 
Robinson, 2018; Stuart et al., 2019). 
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Figure captions  
Figure 1. The effects of hormonal manipulations on % choice bias in male rats. These results 
illustrate the positive and the negative affective biases induced by acute treatment with 
oestradiol, formestane, bisphenol A (panel A) and progesterone, testosterone, flutamide (panel 
B) in male rats (n = 12). Data shown as mean % choice bias ± SEM, *p < 0.05, **p < 0.01, 
***p < 0.001, one sample t-test against a null hypothesised mean of 0% choice bias. 
 
Figure 2. The effects of hormonal manipulations on % choice bias in female rats. The results 
illustrate the positive and the negative affective biases induced by acute treatment with 
oestradiol, formestane, bisphenol A (panel A) and progesterone, testosterone, flutamide (panel 
B) in female rats (n = 12). Data shown as mean % choice bias ± SEM, *p < 0.05, **p < 0.01, 
***p < 0.001, one sample t-test against a null hypothesised mean of 0% choice bias. 
 
Figure 3.  The effects of carbetocin and desmopressin on % choice bias in male and female 
rats. Both male and female rats (n = 12 each) showed significant positive affective biases 
following acute treatment with oxytocin stable analogue, carbetocin (CBT). The graphs also 
demonstrate induction of positive affective bias in male rats following acute vasopressin stable 
analogue, desmopressin (DDAVP) treatment. Vehicle (VEH) treatment did not produce any 
effects. Data shown as mean % choice bias ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, one 
sample t-test against a null hypothesised mean of 0% choice bias. 
 
Figure 4. The effects on food intake following oestradiol, progesterone, testosterone and 
vehicle administration in male (panel A and C, n = 12) and female rats (panel B and D, n = 12). 
Data shown as an absolute consumption [g] and consumption per body weight [g/kg] ± SEM; 









































Supplementary Material  
 
Table S1: List of the substrates used in the experiments in both cohorts. 
 Substrate ‘A’ Substrate ‘B’ Substrate ‘Blank’ 
test 1 felt shredded dishcloth blue exfoliating gloves 
test 2 absorbent fibre string foam shapes 
test 3 dusters tissue paper balls yellow bath sponge 
test 4 black satin cardboard rope 
test 5 fur polyester pompoms 
test 6 cellulose sponge corrugated paper perlite 
test 7 purple ribbon green raffia ribbon sparkly pompoms 
test 8 brown pet bedding cork hessian sack 
test 9 cotton wool balls stringy cloth hairbands 
test 10 organza  silk shredded paper 
test 11 bin liner plastic scourer straws 
test 12 cotton mix leather balloons  
test 13 chubby wool shoe laces velcro 
test 14 brown partition paper dishcloth squares polyester lining 
test 15 aspen cypress coloured matchsticks 
test 16 Christmas ribbon umbrella tights 
test 17 towel canvas pipe cleaners 
test 18 newspaper paper pet bedding confetti 
test 19 suede chenille strands yellow fleece 
test 20 poster squares polystyrene 
polPolystyrene 
sequins 
test 21 crepe paper squares scarf yarn sparkling fibre 






Table S2: Pairing session data following acute hormone manipulations in male rats. Data 
shown as mean (n=12 animals/group) ± SEM averaged from the two pairing sessions for each 




Response latency (s) Trials to criterion 
Vehicle Drug Vehicle Drug 
Oestradiol 
0.00 1.7±0.1 1.6±0.1 8.2±0.4 8.1±0.4 
0.001 1.8±0.2 1.9±0.2 7.9±0.3 8.0±0.5 
0.01 1.6±0.1 1.8±0.1 8.1±0.2 7.8±0.3 
Formestane 
0.00 1.5±0.04 1.4±0.04 6.5±0.1 6.4±0.1 
1.00 1.5±0.05 1.6±0.07 6.4±0.1 6.4±0.1 
10.00 1.5±0.05 1.4±0.04 6.3±0.1 6.4±0.1 
Bisphenol A 
0.00 1.7±0.1 1.7±0.1 6.7±0.2 6.7±0.2 
0.05 1.7±0.1 1.7±0.1 6.9±0.2 6.9±0.3 
0.50 1.9±0.2 1.7±0.1 6.9±0.2 6.8±0.2 
Progesterone 
0.00 1.6±0.1 1.6±0.1 6.4±0.1 6.7±0.2 
1.00 1.5±0.0 1.6±0.1 6.7±0.2 6.6±0.2 
10.00 1.6±0.1 1.6±0.1 6.6±0.2 6.6±0.1 
Testosterone 
0.00 1.9±01 1.9±0.1 7.2±0.3 6.7±0.1 
1.00 1.8±0.1 1.8±0.1 6.7±0.1 7.0±0.2 
10.00 1.9±0.1 1.8±0.1 7.0±0.2 6.9±0.2 
Flutamide 
0.00 1.5±0.1 1.5±0.1 6.4±0.1 6.5±0.1 
1.00 1.6±0.1 1.6±0.1 6.5±0.1 6.5±0.2 
10.00 1.5±0.1 1.5±0.1 6.4±0.1 6.4±0.1 
Vehicle 0.00 1.5±0.1 1.5±0.1 6.4±0.1 6.6±0.2 
Carbetocin 0.30 1.5±0.1 1.6±0.1 6.5±0.1 6.3±0.1 






Table S3: Pairing session data following acute hormone manipulations in female rats. 
Data shown as mean (n=12 animals/group) ± SEM averaged from the two pairing sessions for 




Response latency (s) Trials to criterion 
Vehicle Drug Vehicle Drug 
Oestradiol 
0.00 1.6±0.1 1.5±0.1 6.5±0.1 6.4±0.1 
0.001 1.5±0.1 1.5±0.1 6.3±0.1 6.2±0.1 
0.01 1.7±0.1 1.6±0.1 6.3±0.1 6.4±0.1 
Formestane 
0.00 1.4±0.1 1.5±0.1 6.4±0.1 
± 
6.4±0.1 
1.00 1.5±0.1 1.4±0.0 6.5±0.1 6.3±0.1 




1.7±0.2 6.5±0.1 6.3±0.1 
0.05 1.7±0.1 1.6±0.1 6.2±0.1 6.4±0.1 
0.50 1.6±0.1 1.6±0.2 6.4±0.1 6.3±0.1 
Progesterone 
0.00 1.5±0.0 1.5±0.1 6.6±0.1 6.6±0.1 
1.00 1.5±0.1 1.5±0.1 6.6±0.2 6.5±0.1 
10.00 1.5±0.1 1.6±0.1 6.7±0.1 6.4±0.1 
Testosterone 
0.00 1.5±0.1 1.5±0.1 6.7±0.2 6.5±0.2 
1.00 1.5±0.1 1.4±0.1 6.6±0.3 6.6±0.2 
10.00 1.4±0.1 1.4±0.1 6.5±0.2 6.8±0.2 
Flutamide 
0.00 1.4±0.0 1.5±0.1 6.2±0.1 6.2±0.1 
1.00 1.5±0.1 1.5±0.1 6.3±0.1 6.3±0.1 
10.00 1.5±0.1 1.5±0.1 6.3±0.1 6.2±0.1 
Vehicle 0.00 1.6±0.1 1.7±0.2 6.3±0.1 6.3±0.1 
Carbetocin 0.30 1.7±0.1 1.7±0.2 6.3±0.1 6.4±0.1 
Desmopressin 0.10 1.6±0.1 1.6±0.1 6.3±0.1 6.3±0.1 
 
 
 
